Research programme: recombinant protein therapeutics - Beijing Northland Biotech

Drug Profile

Research programme: recombinant protein therapeutics - Beijing Northland Biotech

Alternative Names: NL 001; NL 202; NL-005

Latest Information Update: 21 Jun 2016

Price : $50

At a glance

  • Originator Beijing Northland Biotech
  • Class Recombinant proteins
  • Mechanism of Action Actin modulators; Angiogenesis inducing agents; Apoptosis inhibitors; Blood coagulation factor replacements; Cell movement activators; Collagen stimulants; Factor X stimulants; Nerve growth factor stimulants; Stem cell stimulants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia A; Myocardial infarction; Psoriasis

Most Recent Events

  • 21 Jun 2016 Preclinical trials in Haemophilia A in China (unspecified route) before June 2016
  • 21 Jun 2016 Preclinical trials in Psoriasis in China (unspecified route) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top